Диссертация (1141356), страница 31
Текст из файла (страница 31)
Klug, J. Reinhardt, C. Schröder.//Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. – 2010. – 53(1). – P. 58-62.113. Kolkundkar, U. Cell Therapy Manufacturing and Quality Control: Current Process and RegulatoryChallenges/ U. Kolkundkar, S. Gottipamula, A. Majumdar //Journal of Stem Cell Research &Therapy. – 2014. – 260. – P. 75-82.114. Labeling of Cellular Therapy Products. ISBT 128 Standard // ICCBBA. – 2013. - ST-004. – P.39.115. Li, M.D.
The global landscape of stem cell clinical trials / M. D. Li, Atkins H., T. Bubela//Regenerative medicine. – 2014. – 9(1). – P. 27-39.116. Maciulaitis, R. Clinical development of advanced therapy medicinal products in Europe: evidencethat regulators must be proactive / R. Maciulaitis, L. D'apote, A. Buchanan et al. //Moleculartherapy: the journal of the American Society of Gene Therapy. – 2012. – 20(3). – P. 479-482.117. MacKay, G. Regenerative medicine annual report/ G.
MacKay, K. Murphy K., M. McGlynn et al.//Alliance for regenerative medicine. – 2013. – P. 71.118. Martin, I. Manufacturing challenges in regenerative medicine/ I. Martin, P.J. Simmons, D.F.Williams //Science Translational Medicine. – 2014. – 6(232). – P. 1-3.119. Martín, P.G. Regulatory considerations in production of a cell therapy medicinal product in Europeto clinical research/ P.G.
Martín, A.R. Martinez, V.G. Lara et al. //Clinical and experimentalmedicine. – 2014. – 14(1). – P. 25-33.142120. Mason, C. Cell therapy industry: billion dollar global business with unlimited potential/ C. Mason,D.A. Brindley, E.J. Culme-Seymour et al. //Regenerative medicine. – 2011. – 6(3). – P. 265-272.121. McBlane, J. W. Preclinical safety testing for cell-based products using animals/ J.W. McBlane//Biologicals. – 2015. – 43(5). – P. 425-428.122.
Migliaccio, G. Role of the EU framework in regulation of stem cell-based products/ G. Migliaccio,C. Pintus // Springer Berlin Heidelberg. - 2012. – 130. - P. 287-299.123. Murphy, M.B. Mesenchymal stem cells: environmentally responsive therapeutics for regenerativemedicine/ M.B. Murphy, K. Moncivais, A.I. Caplan //Experimental & Molecular Medicine. –2013. – 45(11). – P. 1 – 16.124. Pharmaceutical Affairs Act // South Korean Food and Drug Administration [Электронныйресурс].-2010.-Режимдоступа:https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwjQu9yS25TSAhXD_ywKHYe_CGIQFggaMAA&url=http%3A%2F%2Fwww.mfds.go.kr%2Feng%2Feng%2Fdownload.do%3Bjsessionid%3DxVlWEUzfqWBi7ECHIT715aTUpENxrnwAVHaRSgUZCoc86a02XtcKFPFJVM6gphue%3FboardCode%3D16771%26boardSeq%3D67028%26fileSeq%3D1&usg=AFQjCNFDsCcm9rPDNxXRJQqnO7XKGtRig&sig2=xL4ifX9YPFHM6FyQGG-yCA&bvm=bv.147134024,d.bGg, свободный.– Загл.
с экрана.125. Private Hospitals and Medical Clinics Regulation: Private Hospitals and Medicinal Clinic Act//Ministry of Health Singapore [Электронный ресурс]. - 2013. - Режим доступа:http://statutes.agc.gov.sg/aol/search/display/view.w3p;ident=2a19b4d6-f492-4ab4-bdcee48e42233c7d;page=0;query=CompId%3A2a19b4d6-f492-4ab4-bdcee48e42233c7d%20ValidTime%3A20130830000000%20TransactionTime%3A20130830000000;rec=0#legis, свободный. – Загл.
с экрана.126. Ram-Liebig, G. Regulatory challenges for autologous tissue engineered products on their wayfrom bench to bedside in Europe/ G. Ram-Liebig, J. Bednarz, B. Stuerzebecher //Advanced drugdelivery reviews. – 2015. – 82. – P. 181-191.127. Renner, M. Regulation for Gene and Cell Therapy Medicinal Products in Europe/ M. Renner, B.Anliker, E. Flory et al. //Gene Therapy and Cell Therapy through the Liver: Current Aspects andFuture Prospects. – Springer Japan, 2016. – P. 105-123.128. Rustichelli D. Validation of analytical methods in compliance with good manufacturing practice:a practical approach/ D. Rustichelli, S. Castiglia, M.
Gunetti et al. //Journal of translationalmedicine. – 2013. – 11(1). – P. 197.143129. Safety of human cells, tissues and organs for transplantation regulations// Food and Drug Act.Government of Canada [Электронный ресурс]. – 2009. - Режим доступа: http://lawslois.justice.gc.ca/eng/regulations/SOR-2007-118/, свободный.
– Загл. с экрана.130. Summary of the 2015 annual reporting of serious adverse events and reactions for tissues and cells// European Commission Public Health [Электронный ресурс]. – 2015. Режим доступа:http://ec.europa.eu/health//sites/health/files/blood_tissues_organs/docs/2015_sare_summary_en.pdf, свободный. – Загл. с экрана.131. Salmikangas, P. Manufacturing, characterization and control of cell-based medicinal products:challenging paradigms toward commercial use/ P. Salmikangas, M.
Menezes-Ferreira, I. Reischlet al. //Regenerative medicine. – 2015. – 10(1). – P. 65-78.132. Seem, D.L. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, andhepatitis C virus transmission through organ transplantation/ D.L. Seem, I. Lee, C.A. Umscheid etal. //Public Health Reports. – 2013. – 128(4) – P. 247-344.133. Sella, S. General requirement for quality and safety in stem cell and cell-based products fortranslational therapy/ S. Sella, J.C. Francisco, T.M. Madalozzo et al. //Cell Biology: Research &Therapy. – 2014. – 3(1). – P.
2-4.134. Sensebé, L. Production of mesenchymal stromal/stem cells according to good manufacturingpractices: a review/ L. Sensebé, M. Gadelorge, S. Fleury-Cappellesso //Stem Cell Research &Therapy. – 2013. – 3(4). – P. 1-6.135. Shapiro, J.K. FDA’s Regulatory Scheme for Human Tissue/ J.K. Shapiro, B.J. Wesoloski //Human Tissue Regulation. - 2007.
– 11(12) - P. 9-12.136. Sheth-Shah, R. Regulatory requirements in the good manufacturing practice production of anepithelial cell graft for ocular surface reconstruction/ R. Sheth-Shah, A.J. Vernon, S. Seetharamanet al. //Regenerative medicine. – 2016. – 11(3). – P. 307-320.137. Squillaro, T. Clinical trials with mesenchymal stem cells: an update/ T.
Squillaro, G. Peluso, U.Galderisi //Cell transplantation. – 2016. – 25(5). – P. 829-848.138. Syed, B.A. Stem cell therapy market/ B.A. Syed, J.B. Evans //Nature Reviews Drug Discovery. –2013. – 12(3). – P. 185-186.139. The Miracle of Stem Cells / R.J. Howe et al.
– USA: Stemmedia, 2011. - 248 p.140. Thirumala, S. Manufacturing and banking of mesenchymal stem cells/ S. Thirumala, W.S. Goebel,E.J. Woods //Expert opinion on biological therapy. – 2013. – 13(5). – P. 673-691.141. Vigilance and Surveillance of Tissues and Cells in the European Union, Final Recommendations.// European Union Standards and Training for the Inspection of Tissue Establishments[Электронныйресурс].–2010.-Режимдоступа:144http://www.iss.it/binary/ecet/cont/Deliverable_11_Vigilance_Recommendations_Final_June_2010.pdf, свободный. – Загл. с экрана.142.
Voelker, R. FDA grants approval for first cord blood product/ R. Voelker // JAMA. – 2011. –306(22). – P. 2442.143. Waltz, E. Mesoblast acquires Osiris' stem cell business/ E. Waltz //Nature biotechnology. – 2013.– 31(12). – P. 1061.144. Weber D.J. Understanding and Implementing GTPs/ D.J. Weber //Regulatory Focus – 2008. – 9.- P. 19-28.145. Weber, D.J. Navigating FDA Regulations for Human Cells and Tissues/ D.J.
Weber//BioProcessing International – 2004. - 2(8). - P. 22-26.146. WHO good manufacturing practices for biological products: sixty-sixth report, Annex 2, WHOTechnical Report Series №999 // WHO Expert Committee on Biological Standardization. Geneva:WorldHealthOrganization[Электронныйресурс].–2016.-Режимдоступа:http://www.who.int/biologicals/areas/vaccines/Annex_2_WHO_Good_manufacturing_practices_for_biological_products.pdf?ua=1, свободный.
– Загл. с экрана.147. WHO good manufacturing practices for sterile pharmaceutical products: forty-fifth report, Annex6, WHO Technical Report Series №961 // WHO Expert Committee on Specifications forPharmaceutical Preparations. Geneva: World Health Organization [Электронный ресурс]. –2011.-Режимдоступа:http://www.who.int/medicines/areas/quality_safety/quality_assurance/GMPSterilePharmaceuticalProductsTRS961Annex6.pdf?ua=1, свободный. – Загл.
с экрана.148. Womack, C. Human research tissue banks in the UK National Health Service: laws, ethics,controls and constraints/ C. Womack, N.M. Gray //British journal of biomedical science. – 2000.– 57(3). – P. 250-253.149. Yong, K. W. Biobanking of Human Mesenchymal Stem Cells: Future Strategy to FacilitateClinical Applications/ K.W. Yong, J.R. Choi, W.K.Z.W.
Safwani // Biobanking andCryopreservation of Stem Cells. – Springer International Publishing, 2016. – P. 99-110.145ПРИЛОЖЕНИЯПриложение 1.146147Приложение 2..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
